Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivekimig in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT06975722Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of brivekimig in ulcerative colitis (UC), sponsored by Sanofi. Started Jul 2025; status: active, not recruiting.
02
Drugs
brivekimig
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06975722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975722.